November 1, 2016
View Full PaperOne-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation
Structured PICO
Does ProGlide SMCD reduce vascular and bleeding complications compared to Prostar SMCD in patients undergoing transfemoral TAVI?
P
Population
Patients undergoing transfemoral transcatheter aortic valve implantation (TAVI)
I
Intervention
ProGlide suture-mediated closure device (SMCD)
C
Comparator
Prostar suture-mediated closure device (SMCD)
O
Outcome
Vascular and bleeding complicationssafety
The use of ProGlide SMCD for access-site hemostasis in transfemoral TAVI is associated with fewer vascular and bleeding complications than Prostar SMCD.
Abstract
In this analysis, the use of ProGlide SMCD was associated with a reduced risk of vascular and bleeding complications following TAVI compared to Prostar SMCD usage. However, major vascular complications but not ProGlide use did independently predict long-term mortality.